Puma Biotechnology (PBYI) Short term Debt (2019 - 2026)

Puma Biotechnology (PBYI) has 7 years of Short term Debt data on file, last reported at $11.3 million in Q1 2026.

• Quarterly Short term Debt fell 75.11% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (down 75.11% YoY) and the FY2025 annual result came in at $22.5 million, down 50.31% from the prior year.
• Short term Debt retreated to $11.3 million in Q1 2026, from $22.5 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $45.3 million in Q1 2024 to a low of $11.3 million in Q1 2026.
• A 4-year average of $33.0 million and a median of $34.0 million in 2023 frame the typical range for Short term Debt.
• Annual changes were most pronounced in 2024 — Short term Debt jumped 300.01% — and 2026, when it tumbled 75.11%.
• Tracing PBYI's Short term Debt over 4 years: stood at $34.0 million in 2023, then surged by 33.33% to $45.3 million in 2024, then plunged by 50.31% to $22.5 million in 2025, then tumbled by 49.9% to $11.3 million in 2026.
• The last three Short term Debt figures came in at $11.3 million (Q1 2026), $22.5 million (Q4 2025), and $33.7 million (Q3 2025), per Business Quant data.